Eli Lilly unveiled TuneLab, an AI platform granting early-stage biotechs access to proprietary drug discovery models developed using decades of Lilly’s research data. Participating companies contribute anonymized training data via a federated learning system that preserves data privacy, enabling continuous mutual model improvement. Initial models focus on predicting small molecule drug properties and antibody developability, with plans to expand capabilities. This initiative aims to democratize cutting-edge AI resources, accelerating innovation for smaller companies and fostering collaborative advancement across the biotech ecosystem.